Nissan Chemical Industries Limited

Reprocell, Inc.

Norihisa Ishiwata

Katsuaki Miyaji

Yutaka Hirokawa

Shunsuke Iwamoto

Takanori Nakamura

Kazufumi Yanagihara

Shingo Owada

Yukihiro Shigeta

Hirofumi Ota

Satoshi Nakano

Taito Nishino

Masato Horikawa

Yasuyuki Asai

Masao Yamamoto

Koji Toyama

Makiko Yui

Shingo Oowada

Hisao Kamiya

Katsuaki Myaji

Shunuske Iwamoto

Atsushi Miyamura

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar, R, R, R, R, R, Rand Rare defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Method for expanding hematopoietic stem cells using heterocyclic compound

An object of the present invention is to expand CD34cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells. A method for expanding CD34cells, which comprises culturing CD34cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L, L, L, L, R, R, R, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof. 

A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Heterocyclic compounds and thrombopoietin receptor activators

The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective. A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Amide compound and thrombopoietin receptor activator

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators

A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, D is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, and E is a C?2-14#191 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the activator or a solvate thereof, as an active ingredient. 

Pyrazolone compounds and thrombopoietin receptor activator

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Hydrazide compounds and thrombopoietin receptor activators

A compound represented by the formula (I) (wherein R, R, Rand Rare as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Thiophene compounds and thrombopoietin receptor activators

Pyrazole compounds and thrombopoietin receptor activators

A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): [wherein each of Rand Ris independently a hydrogen atom, SOH, a Calkyl group, a Calkylcarbonyl group or a Carylcarbonyl group (the Calkyl group, the Calkylcarbonyl group and the Carylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a Calkenyl group, a Calkoxy group, a Calkoxycarbonyl group, a Caryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group or NRR) , and each of R, Rand Ris independently a hydrogen atom, a hydroxyl group or a Calkoxy group].

Thrombopoetin receptor activator and process for producing the same

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is ORSRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Growing community of inventors

Minamisaitama-gun, Japan

Norihisa Ishiwata